Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Neoplasm, Residual × Letrozole × 90 days × Clear all

Sponsor

Conditions

Breast Neoplasms 57 Endometrial Neoplasms 6 Ovarian Neoplasms 4 Advanced Breast Cancer 4 Polycystic Ovary Syndrome 3 Neoplasms 3 Carcinoma, Intraductal, Noninfiltrating 3 Breast Neoplasms, Male 3 HR+/HER2- Breast Cancer 2 Carcinoma, Non-Small-Cell Lung 2 Uterine Cervical Neoplasms 1 Unilateral Breast Neoplasms 1 Triple Negative Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Recurrence 1 Prostatic Neoplasms 1 Pathologic Complete Response 1 Neoplasms by Site 1 Neoplasm Metastasis 1 Low-Grade Serous Ovarian Cancer 1 Low Grade Serous Ovarian Cancer 1 Locoregional Recurrence 1 Leiomyoma 1 Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer 1 Hereditary Sensory and Autonomic Neuropathies 1 Hemangiosarcoma 1 Head and Neck Neoplasms 1 Fallopian Tube Neoplasms 1 Endometrial Stromal Tumors 1

Interventions

fludarabine 4 Cyclophosphamide 4 blinatumomab 3 Melphalan 3 pembrolizumab 2 fludarabine phosphate 2 Lenalidomide 2 Dexamethasone 2 Cytarabine 2 Capecitabine 2 venetoclax 1 trastuzumab deruxtecan 1 tislelizumab 1 tisagenlecleucel 1 thymoglobulin 1 tetrathiomolybdate 1 tagraxofusp 1 relugolix 1 palbociclib 1 nilotinib 1 ixazomib 1 isatuximab 1 inavolisib 1 giredestrant 1 enzalutamide 1 avelumab 1 abemaciclib 1 Whole-Body Irradiation 1 Trastuzumab 1 Transplantation 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡